针对半月板撕裂或退行性磨损所致慢性膝痛的半月板靶向注射:一项回顾性研究
该回顾性病历回顾纳入135例半月板撕裂或退行性磨损患者,分析超声引导下半月板靶向皮质类固醇注射的镇痛效果。结果显示平均镇痛持续5.68周(SD 5.28),VAS评分从初诊至随访下降2.14(P < .0001),镇痛积分3.98。作者认为20或40 mg曲安奈德半月板靶向注射有明显获益,但受病历回顾和无对照组比较的限制,需未来前瞻性研究比较半月板靶向注射与关节腔内注射。
要点
- 超声引导下半月板靶向注射曲安奈德后平均镇痛持续5.68周(SD 5.28)。
- VAS疼痛评分从初诊至随访下降2.14(P < .0001),镇痛积分3.98。
- 作者认为20或40 mg曲安奈德半月板靶向注射有明显获益,但受病历回顾和无对照组限制。
核心结论
- 研究结果表明20或40 mg曲安奈德半月板靶向注射有明显获益,但受病历回顾研究和无对照组比较的限制;未来需前瞻性研究比较半月板靶向注射与关节腔内注射,以确定治疗半月板撕裂或退行性磨损所致慢性膝痛的更佳方式。
研究设计与样本
- 回顾性病历回顾,纳入135例半月板撕裂或退行性磨损并接受半月板靶向注射治疗的患者,记录治疗前后VAS疼痛评分、疼痛缓解百分比及缓解持续时间;采用超声引导下注射。
诊断标准与关键数值
- 超声引导下半月板靶向皮质类固醇注射(曲安奈德20或40 mg)后平均镇痛持续5.68周(SD 5.28),VAS评分从初诊至随访下降2.14(P < .0001),镇痛积分3.98。
临床应用与阅片要点
- 作者认为20或40 mg曲安奈德半月板靶向注射有明显获益;作者指出未来需前瞻性研究比较半月板靶向注射与关节腔内注射,以确定治疗半月板撕裂或退行性磨损所致慢性膝痛的更佳方式。
局限性
- 病历回顾研究的局限性。
- 无对照组比较。
- 结果突显未来需前瞻性研究比较半月板靶向注射与关节腔内注射。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Meniscal tears caused by acute trauma or degenerative fraying affect a wide array of individuals. An effective, long-lasting treatment has widely been sought after. Intra-articular corticosteroid injections have been among the methods of controlling pain for more than 60 years. However, such injections tend to produce short-lasting results, with profound effects lasting an average of up to 4 weeks. The purpose of this study was to determine the average duration and magnitude of pain relief after meniscal-targeted injections.
METHODS: The electronic medical records of 135 patients were accessed for this retrospective chart review. Patients who had meniscal tears or degenerative fraying and were treated with meniscal-targeted injections were selected. Patients' visual analog scale (VAS) pain scores (before and after treatment) were recorded, along with the percentage of pain relief and duration of pain relief.
RESULTS: Ultrasound-guided meniscus-targeted corticosteroid injections for meniscal tears or degenerative fraying produced 5.68 (SD, 5.28) weeks of pain relief on average, with a decrease in pain from initial to follow-up visits of 2.14 (P < .0001) as per the visual analog scale score, and an Integral of Pain Relief score of 3.98.
CONCLUSIONS: Our findings indicate a substantial benefit from 20- or 40-mg meniscus-targeted triamcinolone injections, granted the limitations of chart review research and no control group comparison. Results highlight the need for future prospective research comparing meniscus-targeted injections with intra-articular injections to identify a better modality for treating patients with chronic knee pain caused by meniscal tears or degenerative fraying.
引用
- Wilderman I, Berkovich R, Meaney C, et al. Meniscus-Targeted Injections for Chronic Knee Pain Due to Meniscal Tears or Degenerative Fraying: A Retrospective Study. J Ultrasound Med. 2019. PMID: 30887572. doi:10.1002/jum.14987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。